Baicalin as a potential candidate for treating systemic sclerosis.

IF 4.6 2区医学 Q2 IMMUNOLOGY

Inflammopharmacology Pub Date : 2025-06-23 DOI:10.1007/s10787-025-01820-z

Giada Cimino, Federica Rapisarda, Rossella Talotta

{"title":"Baicalin as a potential candidate for treating systemic sclerosis.","authors":"Giada Cimino, Federica Rapisarda, Rossella Talotta","doi":"10.1007/s10787-025-01820-z","DOIUrl":null,"url":null,"abstract":"<p><p>Systemic sclerosis (SSc) is a peculiar connective tissue disease characterized by a unique scenario that combines autoreactive cell activation with endothelial dysfunction and tissue fibrosis. Due to the only partially understood pathogenesis, the treatment of the disease is still controversial. Baicalin is a natural flavonoid extracted from the roots of Scutellaria baicalensis. It has been shown to be effective in preclinical models of pulmonary arterial hypertension, trophic ulcers, liver fibrosis, cancer and immune-mediated diseases. Baicalin may act via multiple mechanisms ranging from antagonizing TLR4-induced signaling to inhibiting the TGF-β/Smad3 pathway or enhancing antioxidant mechanisms. These pharmacologic properties make this agent a potential candidate for counteracting the pathogenic triad occurring in SSc. The aim of this narrative review is to summarize current knowledge on the effects of baicalin in contrasting vasculopathy, immune dysfunction and fibrosis and to explain the rationale for its use in SSc. As the efficacy/safety profile of baicalin has not been tested in SSc patients, further studies are indeed warranted.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01820-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Systemic sclerosis (SSc) is a peculiar connective tissue disease characterized by a unique scenario that combines autoreactive cell activation with endothelial dysfunction and tissue fibrosis. Due to the only partially understood pathogenesis, the treatment of the disease is still controversial. Baicalin is a natural flavonoid extracted from the roots of Scutellaria baicalensis. It has been shown to be effective in preclinical models of pulmonary arterial hypertension, trophic ulcers, liver fibrosis, cancer and immune-mediated diseases. Baicalin may act via multiple mechanisms ranging from antagonizing TLR4-induced signaling to inhibiting the TGF-β/Smad3 pathway or enhancing antioxidant mechanisms. These pharmacologic properties make this agent a potential candidate for counteracting the pathogenic triad occurring in SSc. The aim of this narrative review is to summarize current knowledge on the effects of baicalin in contrasting vasculopathy, immune dysfunction and fibrosis and to explain the rationale for its use in SSc. As the efficacy/safety profile of baicalin has not been tested in SSc patients, further studies are indeed warranted.

查看原文本刊更多论文

黄芩苷作为治疗系统性硬化症的潜在候选者。

系统性硬化症（SSc）是一种特殊的结缔组织疾病，其特点是结合了自身反应性细胞活化、内皮功能障碍和组织纤维化。由于发病机制尚不完全清楚，对该病的治疗仍存在争议。黄芩苷是从黄芩根中提取的一种天然类黄酮。它已被证明对肺动脉高压、营养性溃疡、肝纤维化、癌症和免疫介导性疾病的临床前模型有效。黄芩苷可能通过多种机制起作用，从拮抗tlr4诱导的信号传导到抑制TGF-β/Smad3途径或增强抗氧化机制。这些药理特性使该药物成为对抗SSc中发生的致病性三联征的潜在候选药物。这篇叙述性综述的目的是总结黄芩苷在对比血管病变、免疫功能障碍和纤维化方面的作用的现有知识，并解释其在SSc中使用的基本原理。由于黄芩苷的有效性/安全性尚未在SSc患者中进行测试，因此进一步的研究确实是必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

CiteScore

8.00

自引率

3.40%

发文量

200

期刊介绍： Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]